Axsome Therapeutics AXSM Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total costs & expenses?
- Axsome Therapeutics (AXSM) reported total costs & expenses of $254.56M in Q1 2026.
- How has Axsome Therapeutics's total costs & expenses changed year-over-year?
- Axsome Therapeutics's total costs & expenses increased by 42.7% year-over-year, from $178.45M to $254.56M.
- What is the long-term trend for Axsome Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Axsome Therapeutics's total costs & expenses has grown at a 59.4% compound annual growth rate (CAGR), from $124.71M to $805.26M.
- What does total costs & expenses mean?
- The sum of all expenditures required to run the company's operations.
- How do you interpret total costs & expenses?
- An increase faster than revenue growth suggests margin compression and potential sustainability issues.
- How does total costs & expenses compare across companies?
- Used to calculate the overall operating margin when compared against total revenue.